Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Deferred Taxes (2022 - 2025)

Harmony Biosciences Holdings' Deferred Taxes history spans 4 years, with the latest figure at $7.4 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 209.89% year-over-year to $7.4 million; the TTM value through Dec 2025 reached -$7.3 million, up 75.08%, while the annual FY2025 figure was -$7.3 million, 75.08% up from the prior year.
  • Deferred Taxes for Q4 2025 was $7.4 million at Harmony Biosciences Holdings, up from -$3.9 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $7.4 million in Q4 2025 and bottomed at -$14.3 million in Q2 2024.
  • The 4-year median for Deferred Taxes is -$4.3 million (2022), against an average of -$4.2 million.
  • The largest annual shift saw Deferred Taxes tumbled 697.68% in 2024 before it skyrocketed 209.89% in 2025.
  • A 4-year view of Deferred Taxes shows it stood at -$4.3 million in 2022, then skyrocketed by 126.34% to $1.1 million in 2023, then crashed by 697.68% to -$6.7 million in 2024, then surged by 209.89% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Deferred Taxes are $7.4 million (Q4 2025), -$3.9 million (Q3 2025), and -$6.5 million (Q2 2025).